PI3K inhibitors are subdivided into three categories: (i) isoform-specific inhibitors, e.g. GSK2636771 as an inhibitor of PI3Kβ with anti-tumor activity in PTEN-deficient cancers66; (ii) dual PI3K/mTOR inhibitors, such as Dactolisib inhibiting the proliferation and migration of HT-29 human colorectal adenocarcinoma cells67; and (iii) pan-PI3K inhibitors, e.g. DHNQ decreasing Colo-205, and HCT-116 colorectal cell proliferation and survival68. This evidence concerns the gene PIK3CD and neoplasm.